Idorsia (OTCMKTS:IDRSF) Shares Up 1.8% – Should You Buy?

Idorsia Ltd (OTCMKTS:IDRSFGet Free Report) shares were up 1.8% during trading on Monday . The company traded as high as $5.75 and last traded at $5.75. Approximately 300 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 10,019 shares. The stock had previously closed at $5.65.

Idorsia Stock Up 1.8%

The stock’s 50 day moving average is $4.88 and its 200 day moving average is $4.68.

About Idorsia

(Get Free Report)

Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.

Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.

Featured Articles

Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.